bms204352 has been researched along with clomipramine in 4 studies
| Studies (bms204352) | Trials (bms204352) | Recent Studies (post-2010) (bms204352) | Studies (clomipramine) | Trials (clomipramine) | Recent Studies (post-2010) (clomipramine) |
|---|---|---|---|---|---|
| 49 | 1 | 12 | 2,929 | 541 | 304 |
| Protein | Taxonomy | bms204352 (IC50) | clomipramine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.034 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.071 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.241 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.091 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.005 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.053 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.707 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 3.9465 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.091 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.413 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.005 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0505 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.7065 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.005 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.17 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 1.113 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.0678 | |
| Histamine H2 receptor | Homo sapiens (human) | 2.049 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.18 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.067 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.034 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | 0.005 | |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.0002 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.035 | |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | 0.005 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.085 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.139 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.005 | |
| Trypanothione reductase | Trypanosoma brucei brucei | 3.4 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.239 | |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 0.72 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.245 | |
| Voltage-dependent N-type calcium channel subunit alpha-1B | Homo sapiens (human) | 9 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.7615 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 0.005 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 1.362 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.005 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 review(s) available for bms204352 and clomipramine
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
3 other study(ies) available for bms204352 and clomipramine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |